Cyclopropyl Arylpyrazoles for Parasiticidal Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Prior arylpyrazole compounds for parasite control often lack sufficient activity, duration of action, and bioavailability, particularly against a broad spectrum of arthropods, and may have poor pharmacokinetic profiles and safety concerns.
Innovation Solution
Development of C4-(cyclopropyl)arylpyrazole derivatives with specific substituents such as pentafluorothiophenyl and cyclopropyl groups, which enhance bioavailability and duration of action without compromising activity, and improve pharmacokinetic profiles, safety, and solubility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If prior art arylpyrazole compounds are used for parasite control, then some parasiticidal activity is achieved, but the activity and duration of action are insufficient against a broad spectrum of arthropods
Solution Approach 1:
The patent modifies the chemical structure parameters of arylpyrazole compounds by introducing specific substituents at defined positions (R1-R10 groups including cyclopropyl, pentafluorothiophenyl, cyano, and amino groups). These structural parameter changes enhance both the parasiticidal activity and broad-spectrum effectiveness against various arthropods while maintaining reasonable bioavailability
Solution Approach 2:
The invention creates composite molecular structures by combining multiple functional groups (pyrazole core, cyclopropyl rings, pentafluorothiophenyl groups, cyano groups, and amino substituents) into a single molecule. This composite approach allows the compound to interact with multiple parasite targets simultaneously, achieving both high activity and broad-spectrum coverage
2Reliability
If prior art parasiticidal agents are used, then some activity is achieved, but the bioavailability in the treated animal is low leading to poor activity
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular properties such as lipophilicity, molecular weight, and functional group distribution. The specific substituent pattern (combinations of R1-R10 groups) is designed to improve membrane permeability and metabolic stability, thereby increasing bioavailability while maintaining parasiticidal activity
3Reliability
If prior art compounds are used, then some parasiticidal effect is achieved, but the duration of action is short requiring frequent dosing
Solution Approach 1:
The patent extends duration of action by modifying metabolic stability parameters through strategic placement of metabolically stable groups (such as pentafluorothiophenyl and cyclopropyl groups). These structural modifications reduce metabolic degradation rates, increasing the half-life of the compound in vivo and thereby extending the duration of parasiticidal effect
4Reliability
If prior art parasiticidal agents are used, then some activity is achieved, but the pharmacokinetic profile and safety are compromised
Solution Approach 1:
The patent improves safety by introducing selective toxicity through localized functional groups. The specific arrangement of R1-R10 substituents creates molecules that preferentially interact with parasite-specific targets while minimizing interaction with host mammal proteins. This local differentiation of chemical properties enhances the therapeutic index by improving selectivity between parasite and host
Data Source
AI summary
This invention relates to a range of 1-aryl-4-cyclopropylpyrazoles wherein all substituents are as defined in the application in which the cyclopropyl ring is substituted at the angular position, and pharmaceutically acceptable salts and solvates thereof, to compositions comprising such compounds, processes to their synthesis and their use as parasiticides.